FDA Should Relax Endpoint Requirements For Emergency Research, Novo Nordisk Says
This article was originally published in The Pink Sheet Daily
Executive Summary
“Reduction of substantial morbidity alone should be sufficient” benefit in medical trials conducted under emergency conditions, the firm says.